Navigation Links
Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR

e Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements relating to the further development and potential safety and efficacy of KOS-1803 and KOS-1584; and initiations of clinical trials and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, risks related to the development of Kosan's product candidates, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; uncertainties with regards to the development activities that Roche will conduct or permit to be conducted for KOS-1803; and other risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2006 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

CONTACT: Jane Green, VP, Corporate Communications, +1-510-731-5335(office), or +1-415-652-4819 (mobile), or green@kosan.com

Web site: http://www.kosan.com/

Ticker Symbol: (NASDAQ-NMS:KOSN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:3/27/2015)... 27, 2015 Across the global healthcare landscape, ... in clinical development, market education, and regulatory compliance. As ... Affairs function is expected to increase in prominence and ... According to research by benchmarking firm, Best Practices, ... dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... March 27, 2015 Object recognition technology has ... impaired and elderly. The VelaSense ® ... lead more independent, productive and fulfilling lives. VelaSense ® ... allow users to identify objects from a one million ... create customized object databases for personal use. ...
(Date:3/27/2015)... Ga. , March 27, 2015  Holographic Optical ... in the field of holographic medical imaging, is entering ... its Kickstarter campaign. Launching on April 20 th , ... and Voxbox Pro. The 8-inch and 22-inch displays will ... home for the first time. In addition to the ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg, 10 mg, 15 mg, and 20 mg. This product ... ® , which is indicated for the treatment of schizophrenia ...
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced sales ... Sales for the first quarter of 2012 were ... the first quarter of 2011. Income from operations increased 5.3% to ... in the first quarter of 2011. Net income increased 5.6% to ...
Cached Medicine Technology:Mylan Launches Generic Version of Zyprexa® Tablets 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
(Date:3/28/2015)... March 28, 2015 Delaying rotator cuff ... necessary, according to research presented today at the American ... Day. , “Our study compared results for 170 patients ... an additional glenohumeral joint capsule release procedure to relieve ... MD, PhD, lead author from St. George Hospital in ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... Purity Products®, a leading direct to ... of their revolutionary new weight loss product, MuffinStop™. ... placebo-controlled clinical studies to be effective in reducing ... is a combination of two traditionally used botanical ... to create one of the most innovative weight ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... Researchers from the University of Pennsylvania School of Medicine ... determines the development of many cell types, and is ... for the maintenance of stem cells. The findings appear ... inhibitors of Notch may not affect bone marrow stem ...
... 1995, Tapped to Steer the World,s Largest Organization ... WHITE PLAINS, N.Y., April 10 The Leukemia & ... chief executive,officer, with the task of leading the world,s ... strives to find cures and,prolong and enhance the lives ...
... survived exposure, study reports, , , THURSDAY, April 10 (HealthDay ... anthrax vaccine that provides protection against the potentially deadly ... and combining two of anthrax,s lethal toxins, the researchers ... be more effective than vaccines that contain just one ...
... - 7,000 deaths ... significantly reduces pharmacy error risk, - Half of consumers choose their ... ... April 10 One-third of America,s 225,million prescription-takers now report experiencing ...
... N.J., April 10 Hooper Holmes,(Amex: HH ) today ... Executive Officer and that Benjamin A. Currier will continue as,Chairman ... a member of the,Board since May 30, 2007, had been ... basis on February 6, 2008., John W. Remshard, who ...
... state,s elderly, disabled, and ... ... cut hundreds of millions of dollars from Medicaid,programs for the elderly, disabled ... the leaders of Florida,s safety net,hospitals warned today., Besides jeopardizing the ...
Cached Medicine News:Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:The Leukemia & Lymphoma Society Announces Appointment of New President and CEO 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 2Health News:Researchers Pursuing Nasal Anthrax Vaccine 3Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 2Health News:Prescription For Disaster: One-Third of Consumers Experience Prescription Errors, New Survey Finds 3Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 2Health News:Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman 3Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 2Health News:Massive Medicaid Cuts Will Impact All Floridians, Safety Net Hospital Leaders Warn 3
RIA kit for the quantitative determination of autoantibodies to IA-2 in serum...
ELISA kit for the quantitative determination of autoantibodies to IA-2 in serum...
Inquire...
Inquire...
Medicine Products: